Orikine Bio
Sylvain Sachot is a seasoned professional in the investment and biotechnology sectors, currently serving as a Partner, Principal, and Investment Director at Asabys Partners since November 2018. Sachot holds multiple board positions, including board member roles at Gradient Denervation Technologies and Orikine Bio, along with board observer roles at SpliceBio, MedLumics, S.L., and previously at INBRAIN Neuroelectronics. Additional board directorship includes Anaconda BioMed. Prior experience includes roles at Ysios Capital as an Investment Associate and Vall d’Hebron Institute of Research as a Business Analyst. Academic credentials include a PhD in Biology from Nantes Université and an MBA from Esade.
This person is not in the org chart
This person is not in any teams
Orikine Bio
Orikine Bio is a pioneering biotech company dedicated to advancing the field of engineered cytokines with unparalleled biological features for the treatment of immune-mediated diseases. Our core mission is to unlock the untapped potential of cytokines, enabling us to offer transformative therapies that have the power to reshape the lives of patients around the globe.